Biopharmaceutical company UCB (Euronext Brussels:UCB) and Domino Data Lab, a data science platform provider, announced on Monday a strategic collaboration aimed at modernising a Statistical Computing Environment (SCE) for the life sciences industry.
The partnership aims to convert legacy SCE into unified, scalable and flexible platforms to meet the evolving demands of clinical research, regulatory compliance and efficient data analysis.
UCB and Domino Data Lab plan to implement a modern cloud-enabled environment that integrates diverse analytical tools, such as SAS, R and Python, within a unified framework, using Domino's expertise in cloud technologies and open-source support combined with UCB's clinical research and regulatory expertise.
This is intended to enhance research capabilities and maintain compliance with industry standards like GxP, FDA 21 CFR Part 11 and GDPR.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval